Photofrin esophageal

Jin-zhang Zeng, M.D., Ph.D. The Samost Center Shanghai Institutes for Biological Sciences Chinese Academy of Sciences 500 Caobao Road Shanghai 200233, China Phone: + 86 21 54481877 Fax: + 86 21 54971085 E-mail: jzzeng sibs.ac.cn Xiao-kun Zhang, Ph.D. Cancer Center Burnham Institute for Medical Research 10901 N. Torrey Pines Road La Jolla, CA 92037, USA Phone: 858 ; 646-3141 Fax: 858 ; 646-3195 E-mail: xzhang burnham. CONTINGENCIES The subsidiary Axcan Scandipharm is a party to several legal proceedings related to the product line it markets under the name ULTRASE. Lawsuits have been filed and claims have been asserted against Axcan Scandipharm and certain other companies, including the enzyme manufacturer, stemming from allegations that, among other things, Axcan Scandipharm's enzyme products caused colonic strictures. Axcan Scandipharm has been named as a defendant in 12 product liability lawsuits. Of the 12 lawsuits to date, Axcan Scandipharm was dismissed from one, nonsuited in another, settled nine and has one pending. At this time, it is difficult to predict the number of potential cases and because of the young age of the patients involved, Axcan Scandipharm's product liability exposure for this issue in the United States will remain for a number of years. Axcan Scandipharm's insurance carriers have defended the lawsuits to date and Axcan expects them to continue to defend Axcan Scandipharm to the extent of its product liability insurance ; should lawsuits be filed in the future. In addition, the enzyme manufacturer and certain other companies have claimed a right to recover amounts paid defending and settling these claims as well as a declaration that Axcan Scandipharm must provide indemnification against future claims. This lawsuit is based on contractual and common law indemnity issues and the parties have agreed to settle their dispute through binding arbitration. The arbitration has commenced and the plaintiffs alleged that the amount at issue may be in excess of , 000, 000. Axcan Scandipharm denies that such reimbursement is owed and has also responded with counterclaims against the plaintiffs. The majority of the , 000, 000 alleged relates to a patent dispute settlement agreement between the plaintiffs and others. As at September 30, 2002 and 2001, the Company has recorded reserves in the amount of approximately , 900, 000 to cover any future liabilities in connection with the indemnification claims and the lawsuits discussed above that may not be covered by, or exceed, applicable insurance proceeds. While the Company believes that the insurance coverage and provisions taken to date are adequate, an adverse determination of any such claims or of any future claims could exceed insurance coverage and amounts currently accrued. C ; MILESTONE PAYMENTS The agreements with QLT relating to the purchase of PHOTOFRIN provided for milestone payments to be made by Axcan to QLT that could reach a maximum of CDN, 000, 000 upon receipt of certain regulatory approvals for specific or an additional indication for PHOTOFRIN or other conditions. Each milestone payment shall be made at the option of the Company either in cash or in Series B preferred shares or in a combination of cash and preferred shares provided that at least one-half of the milestone payable shall be paid in cash. During the year 2000 CDN, 000, 000 U.S., 378, ; was paid by Axcan in cash upon receipt of regulatory approval to market a new laser for use in conjunction with PHOTOFRIN.

Photofrin esophageal

He intimate association between hematopoietic and endothelial cells is both well established and incompletely defined. During early embryogenesis, the hematopoietic and endothelial lineages arise from a common precursor, the hemangioblast, and share expression of numerous "lineage-specific" molecules. In the adult, endothelial and hemato.
Fig. 4. Evolution of gene regulatory networks during early bilaterian evolution. Colored boxes are transcriptional domains where the state of the domain is dependent upon the presence of the product of the gene of the same color. Stage 1. Initial pattern, similar to that in a Type 1 embryonic system developmental process in which embryonic lineages proceed directly to expression of differentiation genes ; Davidson, 1991; Davidson, 2001 ; . A ; The genes in the box to left transduce spatial embryonic cues thick green arrow ; and activate an initial gene green ; , which in turn activates two additional genes red and orange ; all of which produce transcription factors; the orange gene also crossregulates the red gene. These transcription factors in turn regulate the gene battery to right. This gene battery encodes proteins used for a differentiated cell type a-d each gene has at least two cis-regulatory inputs, indicated in orange and red with `x' denoting other inputs which may vary from gene to gene. B ; Stage 2. Later evolutionary stage: the cell differentiation battery shown in Stage 1 has now been incorporated into a pattern formation system that controls an evolutionarily new morphogenetic process deriving from the state in Stage 1. The additional boxes Stage 2 and Stage 3 ; represent new multicellular spatial transcription domains. Only the red gene from Stage 1 is shown in this figure; the red gene is still activated at its initial embryonic address via the green gene as in the ancestor of Stage 1. A new regulatory linkage has appeared, so that the transcriptional activator from the red gene now controls the purple gene, generating the purple transcriptional domain. A growth circuit has also been added. A second cis-regulatory module has been added to the red gene, allowing it to be activated by the purple gene product or repressed by a signal S ; from the underlying spatial domain Stage 3 ; . The result at Stage 4 is to mount the differentiation gene battery on morphological structure of which the patterning and growth are dependent on the yellow and purple transcriptional domains. Redrawn with permission from Fig. 5.7 of Davidson Davidson, 2001.
The School has attracted highly qualified students, on a continuing basis. The students joining the BBA and iBBA programs have the highest secondary school averages of any undergraduate program at York , and are unsurpassed at any other business school program in Canada. For MBAs, the average GMAT Graduate Management Admissions Test ; has been higher than 600 throughout the 1990s; it surpassed 660 for students entering in 2004-2005. These figures are among the highest in Canada and compare very favorably with most noted programs internationally. The second cohort in the executive MBA program graduated in February 2005; this was a group who began their studies in January 2003. A third impressive class of students began their studies in January 2004, and a fourth in January 2005. This year a scheduling modification was made that allows completion of the executive MBA in 18 months down from 24 months ; elapsed time. This was done without any reduction in contact hours or amending of course coverage. In addition to these major curriculum advances and renewals, the School has continued to revise existing courses and add new elective offerings for its students, reflecting the ongoing pattern of change in the field of management; The Schulich School continues to be very well placed in the most recent rankings done by major publications. Schulich is the topranked Canadian School on international rankings done by The Economist Economist Intelligence Unit ; , by The Wall Street Journal's ranking of `Top International Schools', by Forbes, and by Corporate Knights. In another survey of the prevalence of social and corporate responsibility at some 100 top Schools around the world done by the Aspen Institute for the World Resources Institute, Schulich was identified as one of only six Schools that were characterized as being `on the cutting edge', the highest distinction in that review titled Beyond Grey Pinstripes ; . In world standings, Schulich is ranked 22nd by the Financial Times of London and also by The Economist Economist Intelligence Unit ; , 14th by The Wall Street Journal in its `Top International Schools' survey, and 6th among non-US Schools by Forbes. The gift of the School's benefactor, Seymour Schulich, has provided substantial financial assistance to the School. Perhaps more importantly, the gift and naming of the School have helped to make it visible to external constituencies who previously had not developed a clear perception of the School. Chairs and professorships in the School now total 17. These chairs and professorships represent crucial leadership resources within the School and important sources of visibility in the professional and academic communities. Although one of the School's main priorities remains the expansion of its tenure stream cohort to acceptable levels, there has been significant progress in 2003-2004 and 2004-2005 with a total of ten additional faculty joining the School over that two year period.

Photofrin france

Cotherapy we measured use over the previous 3 months only ; or with low satisfaction with pharmacotherapy. In conclusion, in patients seeking care in a primary care clinic setting, the use of herbal medication was specifically associated with a diagnosis of major depression, as well as a lower burden of medical illness and a higher education. The rate of use is fairly low in this group 11% ; , lower than the rate reported in two prior surveys of psychiatric outpatients, and not different from that observed in community surveys. Nonetheless, the use of herbal medicine that was concomitant with anti-anxiety pharmacotherapy was noteworthy, given that approximately half of this primary care sample was using psychotropic medications. Even though only a handful of interactions have been reported thus far, the fact that the range of effects that herbal remedies have on drug metabolic enzymes is still poorly appreciated10 underscores the need for clinicians treating anxious and depressed patients to ask about the use of herbal and other complementary and alternative medicines. This study was supported by NIMH grants MH-57835 and MH-64122 Murray B. Stein, M.D., M.P.H. ; , MH57858 and MH-065324 Peter Roy-Byrne, M.D. ; , and MH58915-03 Michelle Craske, Ph.D and pilocarpine. N 12 livers for CYPs 1A2, 2B6, and 3A; n 10 for CYP2C19, with poor metabolizer livers L11 and L12 excluded; n 11 livers for CYP2D6, with poor metabolizer liver L8 excluded. Ratios of RAF estimates to immunochemically determined CYP contents are also provided. Boldface entries are sample medians, with range of values in parentheses and interquartile range in brackets. r1 refers to the nonparametric Spearman correlation coefficient between the ratio of RAF to immunochemically determined content of a CYP isoform, and the molar ratio of OR to the CYP isoform. r2 refers to the nonparametric Spearman correlation coefficient between the ratio of RAF to immunochemically determined content of a CYP isoform, and the molar ratio of cytochrome b5 to the CYP isoform. Unless otherwise indicated, P .05 for Spearman correlation coefficients. NS, nonsignificant. CYP CYP Content pmol mg Index Reactiona RAF pmol mg RAF: CYP Content Ratio r1 RAF: CYP vs. OR: CYP ; r2 RAF: CYP vs. b5: CYP.

Department of Product Development, Sanquin Plasma Products, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. 2 Sanquin Research and Landsteiner Laboratory of the Academic Medical Center of the University of Amsterdam, The Netherlands and pima.

23. Commitments and Contingencies continued ; b ; Contingencies continued ; Company believes that the insurance coverage and provisions taken to date are adequate, an adverse determination of any present and future claims or of future claims could exceed insurance coverage and amounts currently accrued. c ; Milestone payments The agreements with QLT Phototherapeutics Inc. "QLT" ; relating to the purchase of PHOTOFRIN provided for milestone payments to be made by Axcan to QLT that could reach a maximum of CDN, 000, 000 upon receipt of certain regulatory approvals for specific or additional indication for PHOTOFRIN or other conditions. Each milestone payment shall be made at the option of the Company either in cash or in Series B preferred shares or in a combination of cash and preferred shares provided that at least one-half of the milestone payable shall be paid in cash. During the years 2004, 2003 and 2000 CDN, 000, 000, CDN, 000, 000 and CDN, 000, 000 US, 919, 417, US, 646, 973 and US, 378, ; was paid by Axcan in cash upon receipt of regulatory approvals and was recorded in intangible assets. The agreement to acquire the exclusive licence for North America, the European Union and Latin America to develop, manufacture and market ITAX provides for milestone payments for an amount of , 000, 000 upon regulatory submission and an amount of , 000, 000 upon regulatory approval. The Company will also pay royalties of 9% of net sales from the date of first commercial sale until the expiration of the patent and 6% for ten years then after. d ; Royalties Net sales of certain products of the Company are subject to royalties payable to unrelated third parties. In particular, the Company must pay a 6% royalty on net sales of ULTRASE and 5% royalty on the net sales of ADEK's respectively covered under agreements for the exclusive rights to market these products. Axcan has to pay 5% of worldwide sales of PHOTOFRIN with a maximum of 0, 000 per year and a maximum total aggregate of , 108, 245 until December 2007. Until September 30, 2004, an amount of , 420, 419 has been accounted for , 032, 777 in 2003 and 3, 134 in 2002 ; . Axcan also has to pay 5% of net sales of PHOTOFRIN for use in the therapeutic treatment of cancer and 2% of net sales for other uses until December 2009. Royalties amounting to , 760, 945, , 387, 092 and , 731, 113 respectively for years ended September 30, 2004, 2003 and 2002 were charged to earnings. e ; Licensing During the year 2000, Axcan entered into a new licensing agreement to market a new generation of pancrelipase minitablets. As at September 30, 2004, the Company paid , 500, 000 in development fees, which is the total amount of development fees the Company agreed to pay. Axcan will pay royalties of 6% on the first , 000, 000 of annual sales and 5% on annual sales in excess of , 000, 000.

Photofrin ipsen

Cell Cultures and Tumors. Mouse SCCVII squamous cell carcinoma cells 26 ; were cultured in alpha minimal essential medium Sigma Chemical Co., St. Louis, MO ; supplemented with 10% fetal bovine serum HyClone Laboratories, Inc., Logan, UT ; . Human umbilical vein endothelial cells were grown on 0.8 mg mL fibronectin-coated dishes in medium 199 Sigma Chemical ; containing 10% horse serum HyClone Laboratories ; and glutamine at 292 Ag mL and they were used within the first four passages of the primary culture. The experimental tumors were initiated by injecting s.c. 30 AL of suspension containing 1 106 SCCVII cells into lower dorsal region of syngeneic 7- to 9-week-old female C3H HeN mice. The tumors were treated by PDT when they reached 7-8 mm in largest diameter. The experimental procedures involving mice were approved by the Animal Care Committee of the University of British Columbia. Photodynamic Therapy In vitro and In vivo. The photosensitizer Photofrin used for PDT was provided by Axcan Pharma, Inc. Mont SaintHilaire, Quebec, Canada ; . For in vitro PDT, cells growing in 30-mmdiameter Petri dishes were incubated with Photofrin 5-50 Ag mL in complete growth medium ; , and 24 hours later the Petri dishes were rinsed with cold PBS, placed on ice and exposed to a beam of 630 F 10 nm light for the exposure of 1 J cm2 15 mW cm2 ; . For in vivo PDT, mice were injected Photofrin 10 mg kg i.v. ; , and 24 hours later the tumors were treated with 630 F 10 nm light 150 J cm2; 110-120 mW cm2 ; while the mice were restrained unanesthetized in holders exposing their backs. The chosen PDT dose would cure SCCVII tumors in 5 of mice. The light was generated by a high throughput fiber illuminator Sciencetech, Inc., London, Ontario, Canada ; equipped with 150 W QTH lamp with integrated ellipsoidal reflector and 630 F 10 nm interference filter. A liquid light guide, model 77638 8-mm core diameter, Oriel Instruments, Stratford, CT ; , was used for delivering light for monodirectional superficial illumination. The effect of PDT in vitro was compared with that of edelfosine Calbiochem, Merk KGaA, Darmstadt, Germany ; added at 25 Ag the growth medium for 1 hour at 37jC. Flow Cytometry Analysis. After in vitro PDT, the cells were incubated for different time intervals in complete growth medium at 37jC and then detached using rubber policeman. For staining of cell surface expressed HSPs, the samples were incubated 20 minutes on ice with the following antibodies: mouse anti-HSP60 SPA-829 ; monoclonal antibody or goat anti-HSP60 polyclonal antibody K-19 ; , chicken anti-HSP70 polyclonal antibody K-20 ; or FITC-conjugated mouse anti-HSP70 monoclonal antibody SPA-810FI ; , goat anti-GRP78 polyclonal antibody C-20 ; , and rabbit anti-GRP94 polyclonal antibody H-212 ; . All these antibodies obtained after immunization with human HSP or recombinant peptides mapping its segments ; are cross-reactive with mouse equivalents. They recognize epitopes localized near the COOH terminus of HSP molecules, except for SPA-829 which recognizes a HSP60 region amino acids 288-366 ; nearer to the NH2 terminus 27 ; . The antibodies SPA-829 and SPA-810FI were obtained form Stressgen Biotechnologies Victoria, British Columbia, Canada ; , whereas the other anti-HSP antibodies were purchased from Santa Cruz Biotechnology, Inc. Santa Cruz, CA ; . Secondary antibodies conjugated with FITC used for the visualization of HSP staining were donkey anti-goat IgG 705-095-147 ; and donkey anti-rabbit IgG 711-095-152 ; from Jackson ImmunoResearch Laboratories, Inc. West Grove, PA ; as well as goat anti-chicken IgY Gallus Immunotech, Inc. Fergus, Ontario, Canada ; . In all cases, isotype control staining was also done and if necessary the fluorescence values obtained were used for the background subtraction. ChromPure whole molecule chicken IgY, mouse IgG, goat IgG and rabbit IgG Jackson ImmunoResearch Laboratories ; were used for isotype controls, except for FITC-conjugated ChromPure Mouse IgG also from Jackson and pindolol.

Generic Photofrin

71. Dumon JF, Shapshay S, Bourcereau J et al. Principles for safety in application of the Neodymium-YAG laser in bronchology. Chest 1984; 86: 163-8. Livinston DR, Metha AC, Golish JA et al. Palliation of malignant tracheobronchial obstruction by Nd-YAG laser An update of experience at the Cleveland Clinic Foundation. JAOA 1987; 226-34. 73. Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 579-87. Sutedja G, Bans G, Schaake-Koning C, Van Zandwijk N. High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24: 551-3. Goldman JM, Bulman AS, Rathmel AJ et al. Physiological effects of endobronchial radiotherapy in patients with major airway occlusion by carcinoma. Thorax 1993; 48: 110-4. Stout R, Burt PA, Barber PV et al. HDR brachytherapy for palliation and cure in bronchial carcinoma; The Manchester experience using a single-dose technique. Selectron Brachytherapy J 1990; Suppl 1 ; : 48-53. 77. Bedwinek J, Petty A, Bruton Ch et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992; 22: 22-30. Macha HN, Coch K, Stadler M et al. New techniques for testing occlusive and stenosing tumour of the trachea and main bronchi: Endobronchial irradiation by high dose Indium 192 combined with laser utilization. Thorax 1987; 42: 511-5. Zajac AJ, Kohn ML, Heiser D et al. High dose rate intraluminal brachytherapy in the treatment of endobronchial malignancy. Radiology 1993; 187: 571-5. Tredaniel J, Hennequin C, Zalcman G et al. Prolonged survival after high dose rate endobronchial radiation for malignant airway obstruction. Chest 1994; 105: 767-72. Balchum OJ, Doiron DR. Photoradiation therapy of endobronchial lung cancer Large obstructing tumours, non-obstructing tumours and early stage bronchial cancer lesions. Clin Chest Med 1985; 6: 255-75. Hugh-Jones P, Gardner WN. Laser photodynamic therapy for inoperable bronchogenic squamous caricnoma. Quart J Med 1987; 64: 565-82. Lam S, Kostashuk EC, Coy P. A randomized comparative study of the safety and efficacy of photodynamic therapy using Photofrin D combined with palliative radiotherapy versus palliative radiotherapy alone in patients with inoperable obstructive non-small cell lung bronchogenic carcinoma. Photochem Photobiol 1987; 46: 893-7. MCaughan JS, Williams TE, Bethel BH. Photodynamic therapy of endobronchial tumours. Lasers Surg Med 1986; 6: 336-45. Pass HI, Delaney T, Smith PD et al. Bronchoscopic phototherapy at comparable dose rates: Early results. Ann Thorac Surg 1989; 47: 693-9. Received 19 December 1994; accepted 7 April 1995. Correspondence to: Paul Baas, M.D., Ph.D. Department of Chest Oncology The Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam The Netherlands.

Photofrin alcohol

Question: What are bio-identical hormones? Answer: Bio-identical hormones are hormones that are identical in their molecular structure to the hormones found in your body. Your body recognizes them as "self", not as a foreign substance and pitocin. DMXAA 5, 6-dimethylxanthenone-4-acetic acid ; is an antivascular agent that exerts its antitumor effect at least partly through the induction of tumor necrosis factor TNF ; - . Photodynamic therapy PDT ; , the activation of a photoreactive drug in tumor tissue with visible light, is used clinically to control solid malignancies. PDT has been shown previously to be potentiated, in mice, by the i.p. administration of recombinant human TNF- . Here, we investigated the activity of DMXAA as a modifier of Photofrin-based PDT of implanted murine RIF-1 tumors. The DMXAA dose 20 mg kg 1 ; used throughout this study had little effect on tumor growth. The combination of DMXAA and PDT led to a reduction in tumor volume and significant delays in regrowth, giving a PDT-dose modification factor of 2.81. This enhancement was found to be strongly schedule dependent. The most pronounced responses were achieved when DMXAA was administered 13 h before the local illumination of the tumors; less activity was observed at other intervals within 24 h of PDT-light delivery. Using a 2-h DMXAA-light interval, histological examination showed significantly reduced blood vessel counts CD31 immunostaining ; and marked necrosis H&E ; in the tumors given combination therapy compared with the tumors given either agent alone. Conversely, peritumoral tissue was still intact 24 h after the combined therapy. DMXAA did not augment the damage to normal mouse feet after low-dose PDT 1.5 mg kg 1 Photofrin however, there was some enhancement of normal tissue phototoxicity when DMXAA was combined with high-dose PDT. The antitumor effect after DMXAA plus low-dose PDT 1.5 mg kg 1 Photofrin ; appeared to be dependent on TNF- because neutralizing antibodies to this cytokine reduced the tumor response to control levels. DMXAA by itself induced TNF- in RIF-1 tumors whereas PDT did not. However, the addition of PDT after DMXAA resulted in decreases in TNF- , suggesting that the enhanced antitumor activity of the combination therapy was not attributable simply to an increased induction of the cytokine by PDT over that from DMXAA alone. These observations suggest a promising new combination therapy with considerable therapeutic advantage. Resonance contrast agent iron oxide ; along with a therapeutic agent Photofrin ; . The ability of vascular targeting along with imaging capability while carrying a pay load of a drug by these nanoparticles proves for a multifunctional nanoparticle technology that can be adapted for other diagnostic or therapeutic purposes in future studies. Nanoparticle formulation of Photofrin provides interesting possibilities for new avenues to significantly improve PDT. For example, the traditional delay between Photofrin administration and light exposure 24 hours ; needed to allow for enough clearance from normal adjacent tissue to occur along with prolonged cutaneous photosensitization are well-known disadvantages of PDT. However, these disadvantages were not observed in the application in this study involving targeted Photofrin. Furthermore, vascular targeting of a photosensitizing agent is required to produce irreversible damage of the tumor vascular system leading to ischemia resulting in tumor necrosis 43 45 ; . This is especially important because and posture.

Photofrin patients

Concentration-time data were collected from 3, 12, 19, and 10 patients after 75, 875, 1, and 2 mg photofrin kg body weight DRUG NAME PHOSLO PHOSPHATE-REMOVING AGENTS PHOSPHOLINE IODIDE PHOTOFRIN phrenilin w caffeine & codeine PHYSIOLYTE PHYSIOSOL PILOCARPINE HCL TABLETS PILOPINE HS pindolol PIPERACILLIN SODIUM piroxicam pitocin PLAN B PLAQUENIL plaretase 8000 PLASMA-LYTE PLATINOL AQ PLAVIX PLENAXIS PLENDIL PLETAL PODOCON 25 IN BENZOIN TIN podofilox polycin b poly-dex polyethylene glycol POLYGAM S D POLYMYXIN B SULFATE polymyxin b sulfate trime POLY-PRED POLYTRIM PONSTEL portia-28 potassium chl normal saline potassium chloride potassium chloride er POTASSIUM CITRATE potassium cl-d5w-nacl POTASSIUM-REMOVING AGENTS POTASSIUM-SPARING DIURETICS PRANDIN PRAVACHOL pravastatin sodium prazosin hcl PRECOSE PRED FORTE PRED MILD PRED-G PRED-G S.O.P. PREDNICARBATE prednisol PREDNISOLONE 5MG 5ML syrup and 5 MG tablet prednisolone acetate prednisolone sodium phosp prednisolone sodium phosp prednisolone syrup prednisone 1, 2.5, 5, MG tablets PREDNISONE 50 MG PREDNISONE INTENSOL Oral Concentrate PREDNISONE ORAL SOLUTION PREFEST PREGNYL W DILUENT BENZYL PRELONE PREMARIN TABLETS AND VAGINAL CREAM PREMASOL 10% IV premasol solution for IV PREMPHASE PREMPRO PRENATAL RX PREVACID PREVACID NAPRAPAC PREVACID SOLUTAB prevalite previfem PREVPAC PREZISTA DRUG TIER Tier 2 Tier 2 Tier 4 Tier 1 Tier 3 Tier 3 Tier 1 Tier 2 Tier 1 Tier 3 Tier 1 Tier 1 Tier 2 Tier 3 Tier 1 Tier 2 Tier 3 Tier 2 Tier 4 Tier 3 Tier 3 Tier 2 Tier 1 Tier 1 Tier 1 Tier 1 Tier 4 Tier 3 Tier 1 Tier 2 Tier 3 Tier 3 Tier 1 Tier 1 Tier 1 Tier 1 Tier 2 Tier 1 PAGE NUMBER 18 22 REQUIREMENTS LIMITS and pram.

HELIZIDE The Company is in the process of qualifying a manufacturer of the biskalcitrate potassium bismuth salt ; a component of Helizide combination therapy for the eradication of Helicobacter Pylori bacterium. Axcan anticipates FDA resubmission by December 2004. Assuming approval, we expect to launch the product in the second half of fiscal 2005. Research and development Phase III studies -SALOFALK 750 milligram tablets Axcan completed a Phase III trial, for the Canadian market, on the efficacy and safety of a new 750-milligram mesalamine 5-ASA ; tablet for the oral treatment of ulcerative colitis. The Company filed a supplemental New Drug Submission for approval in Canada in the first quarter of fiscal 2004 and hopes to launch the product in Canada in fiscal 2005. CANASA SALOFALK rectal gel Axcan is currently completing Phase III studies to confirm the efficacy and safety of a new mesalamine rectal gel in the treatment of distal ulcerative colitis. Final results will be available in the second half of fiscal 2004. Assuming the results of the Phase II studies are positive, the Company plans to submit regulatory filings for approvals in the United States and Canada and hopes to launch the rectal gel in the United States and Canada in fiscal 2005. HEPENAX L-Ornithine L-Aspartate salt "LOLA" ; , which is known as HEPENAX, was developed by Merz Pharmaceuticals GmbH in Germany and is licensed to Axcan. The Company intends to further develop HEPENAX in North America and Europe for patients suffering from Porto-Systemic Encephalopathy "PSE" ; . The Company will conduct a Phase II III clinical development program for HEPENAX and plans to seek approval of the intravenous formulation to treat the acute symptoms of PSE. The Company intends to initiate its clinical research program in the third quarter of fiscal 2004 and complete such studies in fiscal 2005. PHOTOFRIN PHOTOFRIN is approved in a number of countries for the treatment of different forms of cancers. Axcan is currently investigating the use of PHOTOFRIN for the treatment of cholangiocarcinoma, a serious bile duct liver ; cancer with a high morbidity rate. The treatment under investigation combines PHOTOFRIN with PDT and the stenting of the bile ducts. The proposed Phase III study will start in the third quarter of fiscal 2004. Pre-Clinical, Phase I and II studies The FDA has accepted an Investigational NDA for NCX-1000, a patented nitric oxide derivative of ursodiol, for the treatment of portal hypertension, a late stage complication of chronic liver disease. The Phase I clinical development program, which is designed to demonstrate the tolerability and safety of NCX-1000, is almost completed. Phase II studies are planned to begin during fiscal 2005. Completion of the entire clinical program is expected to occur in calendar year 2006. Ursodiol Disulfate Axcan recently completed a proof of concept study in rats to evaluate the effect of ursodiol disulfate on the development of colonic tumors. Axcan intends to initiate animal toxicity studies in the third quarter of fiscal and photofrin.

Buy Photofrin online

Photofrin online

Spanish flu in canada, lamictal wiki, lorcet site wikipedia.org, salmonella peanuts and thallium cologne reviews. Cipro not working, co payment define, folinic acid cream and dursban eliminator or babesiosis epidemiology.

Photofrin wiki

Photofrjn, photorrin, pphotofrin, photofrun, pohtofrin, photofrkn, pgotofrin, photofrln, photof5in, photofrrin, phktofrin, photof4in, photofrib, phofofrin, photovrin, photforin, 0hotofrin, ph0tofrin, phootofrin, pyotofrin.

Photofrin prescribing information

Photofrin esophageal, photofrin france, photofrin ipsen, generic photofrin and photofrin alcohol. Photofrin patients, buy photofrin online, photofrin online and photofrin wiki or photofrin prescribing information.

Free Web Hosting by BlackAppleHost.com, a free web hosting division of WiredHub.net